Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
The British Journal of Radiology|August 11, 2021
Total tumor burden in lymphoma - an evolving strong prognostic parameterMichel Meignan, Anne-Segolene Cottereau, Lena Specht, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 11, 2024
Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN NetworkLaure Al Mansour, Louis De Mestier, Magalie Haissaguerre, et al.Hematological Oncology|May 23, 2022
Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic studyRexhep Durmo, Benedetta Donati, Louis Rebaud, et al.Thyroid : Official Journal of the American Thyroid Association|February 16, 2022
Redifferentiating Effect of Larotrectinib in NTRK-Rearranged Advanced Radioactive-Iodine Refractory Thyroid CancerLionel Groussin, Hélène Theodon, Laura Bessiene, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 2024
Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN NetworkAurelien Fosse, Julien Hadoux, Paul Girot, et al.Clinical Nuclear Medicine|February 9, 2023
Positive Correlation Between 18 F-FDG Uptake and Tumor-Proliferating Antigen Ki-67 Expression in Adrenocortical CarcinomasRossella Libé, Aurore Pais, Florian Violon, et al.Blood|January 25, 2020
High total metabolic tumor volume at baseline predicts survival independent of response to therapyLaetitia Vercellino, Anne-Segolene Cottereau, Olivier Casasnovas, et al.Pageof 1